Press release
Acromegaly Pipeline Insights and Clinical Trials Report 2023
Key Takeaways from the Acromegaly Pipeline Report
• Over 15+ Acromegaly companies are evaluating 15+ Acromegaly pipeline therapies in various stages of development, and their anticipated acceptance in the Acromegaly market would significantly increase market revenue.
• The leading Acromegaly Companies includes Ionis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus, Ono Pharmaceutical, Aquestive Therapeutics, Strongbridge Biopharma, Italfarmaco, Ipsen, Antisense Therapeutics, Dauntless Pharmaceuticals, TTY Biopharm, Peptron, DexTech Medical AB, Rani Therapeutics, OPKO Health, Inc., Amolyt Pharma, Foresee Pharmaceuticals, ADVANZ PHARMA, and others.
• Promising Acromegaly Pipeline Therapies includes octreotide FluidCrystal® injection depot, IONIS-GHR-LRx, SRL, Paltusotine, CAM2029 (octreotide subcutaneous depot), and others.
• The Acromegaly companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The Acromegaly pipeline therapies under development are focused on novel approaches to treat/improve Acromegaly.
Request a sample and discover the recent breakthroughs happening in the Acromegaly pipeline landscape @ Acromegaly Pipeline Outlook Report- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Acromegaly Overview
Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. In adults, too much of this hormone causes bones, cartilage, body organs, and other tissues to increase in size. Common changes in appearance include enlarged or swollen nose, ears, hands, and feet. Acromegaly is most often diagnosed in middle-aged adults, but symptoms can appear at any age.
Acromegaly Emerging Drugs Profile
• IONIS-GHR-LRX: Ionis Pharmaceuticals
IONIS-GHR-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of the growth hormone receptor (GHr) to decrease the circulating level of insulin-like growth factor-1 (IGF-1). IGF-1 is a hormone primarily produced in the liver that plays an important role in childhood growth and has anabolic effects in adults. Several different diseases result from abnormally low or high levels of IGF-1, or an inappropriate response to this hormone. When produced in excess, IGF-1 results in acromegaly, a chronic, slowly progressing and life-threatening disease. Currently, it is in Phase II stage of development to treat Acromegaly.
• Paltusotine: Crinetics Pharmaceuticals
Paltusotine (formerly CRN00808) is an orally available nonpeptide biased agonist that is designed to be highly selective for the somatostatin type 2 receptor. It was designed by the Crinetics discovery team to provide a once daily oral option for patients with acromegaly and neuroendocrine tumors that are currently treated by injected therapies that sell approximately $3.1 billion annually. Non-clinical chronic toxicology studies are complete and no dose limiting toxicity was identified at the maximum feasible doses in rats and dogs. Crinetics previously completed a Phase 1 trial that showed potent suppression of the growth hormone (GH) axis in healthy volunteers, which provided clinical proof-of-concept. In addition, the molecule's observed plasma half-life of approximately 2 days suggested the potential for paltusotine for once daily oral administration. A subsequent Phase 1 trial showed that paltusotine was 70% orally bioavailable. Paltusotine is an investigational drug currently undergoing two Phase 2 clinical trials for the treatment of acromegaly, the ACROBAT Edge and Evolve trials. Paltusotine has been discovered, characterized, and developed by Crinetics and U.S. patents have been issued covering paltusotine to 2037. Currently, it is in Phase III stage of development to treat Acromegaly.
Find out more about the Acromegaly Diagnosis and Treatment of patients @ Acromegaly Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Acromegaly Key Companies and Pipeline Therapies
• octreotide FluidCrystal® injection depot: Ionis Pharmaceuticals
• IONIS-GHR-LRx: Crinetics Pharmaceuticals
• SRL: Camurus
• Paltusotine: Ono Pharmaceutical
• CAM2029 (octreotide subcutaneous depot): Aquestive Therapeutics
Acromegaly Pipeline Therapeutics Assessment
Phases
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Discover more about the list of Acromegaly FDA-approved drugs for Acromegaly @ Acromegaly Treatment Landscape- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Acromegaly Pipeline Report
• Coverage- Global
• Acromegaly Companies- Ionis Pharmaceuticals (NYSE: IONS), Crinetics Pharmaceuticals (NYSE: CRNX), Camurus (NYSE: CAMX), Ono Pharmaceutical (NYSE: OPHLF), Aquestive Therapeutics (NYSE: AQST), Strongbridge Biopharma (NYSE: SBBP), Italfarmaco, Ipsen, Antisense Therapeutics (NYSE: ATHJF), Dauntless Pharmaceuticals, TTY Biopharm, Peptron, DexTech Medical AB (NYSE: DEX), Rani Therapeutics (NYSE: RANI), OPKO Health Inc (NYSE: OPK)., Amolyt Pharma, Foresee Pharmaceuticals, ADVANZ PHARMA, and others.
• Acromegaly Pipeline Therapies- octreotide FluidCrystal® injection depot, IONIS-GHR-LRx, SRL, Paltusotine, CAM2029 (octreotide subcutaneous depot), and others
• Acromegaly Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for Acromegaly Emerging Therapies and Ongoing Clinical Trials; visit @ Acromegaly Emerging Therapies and Key Players- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Acromegaly: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Paltusotine: Crinetics Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. IONIS-GHR-LRX: Ionis Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. RaniPill: Rani Therapeutics
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. AZP-3800: Amolyt Pharma
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Acromegaly Key Companies
20. Acromegaly Key Products
21. Acromegaly- Unmet Needs
22. Acromegaly- Market Drivers and Barriers
23. Acromegaly- Future Perspectives and Conclusion
24. Acromegaly Analyst Views
25. Acromegaly Key Companies
26. Appendix
For further information on the Acromegaly Pipeline therapeutics, reach out to Acromegaly Future Perspectives and Unmet Needs- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acromegaly Pipeline Insights and Clinical Trials Report 2023 here
News-ID: 3046288 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Acromegaly
Rising Hormonal Disease Prevalence Powers Growth In The Acromegaly Market: Key F …
The Acromegaly Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Acromegaly Market Size During the Forecast Period?
The market size for acromegaly has experienced swift expansion in the latest years. It is projected to rise from $2.15 billion in 2024 to $2.57…
Acromegaly Global Market Report 2025: Surge in Acromegaly Cases Driving Market G …
Rapid growth is expected in the Acromegaly global market, driven by rising awareness, government initiatives, and demand for effective treatments.
What Is The Projected Market Size Of The Global Acromegaly Global Market Report 2025 And Its Growth Rate?
The acromegaly market size is set for considerable growth in the coming years. Key statistics include:
• The market size grew from $2.15 billion in 2024 to an estimated $2.57 billion in 2025.
• This represents…
Exploring Acromegaly Treatment Market Growth
The global acromegaly treatment market is experiencing robust growth, with no signs of slowing down. In 2023, this market reached a significant milestone, boasting a total value of USD 1.61 billion. The future looks even more promising, with a projected compound annual growth rate (CAGR) of 7.65% from 2024 to 2032. By the end of this period, the market is expected to soar to approximately USD 3.12 billion. But what's…
Acromegaly Market - Defeating Acromegaly, Restoring Lives
Newark, New Castle, USA: The "Acromegaly Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Acromegaly Market: https://www.growthplusreports.com/report/acromegaly-market/8421
This latest report researches the industry structure, sales, revenue, price and…
Acromegaly - Drug Pipeline Landscape, 2022
Acromegaly is a rare hormonal condition that results from an excess amount of growth hormone (GH) in the body. The extra amount of GH causes excess growth in the bones and soft tissues of the body. Children with the condition can grow to abnormal heights.
The most common cause of acromegaly is a tumor in your pituitary gland called a pituitary adenoma that causes pituitary gland to release excess growth hormone…
Acromegaly - Drug Pipeline Landscape, 2022
Acromegaly is a rare hormonal condition that results from an excess amount of growth hormone (GH) in the body. The extra amount of GH causes excess growth in the bones and soft tissues of the body. Children with the condition can grow to abnormal heights.
The most common cause of acromegaly is a tumor in your pituitary gland called a pituitary adenoma that causes pituitary gland to release excess growth hormone…
